Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

(ECOG-ACRIN Cancer Research Group) PrECOG, LLC is reporting on its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma. The trial evaluated adding durvalumab, an immune checkpoint antibody targeting PD-L1, to pemetrexed and cisplatin chemotherapy in 55 patients of any histologic subtype. The study met its primary endpoint with a median overall survival of 20.4 months as compared to the historical control of 12.1 months. The combination was well-tolerated with no unexpected toxicities.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy. The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR T-cell therapy. This latest therapy will be tested in a phase I, dose-escalation clinical trial. It will involve the removal and genetic modification of a patient’s T cells, a type of white blood cell, that will be separated in the la...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsPlatinum ‐based chemotherapy followed by lung‐sparing surgery (P/D) and IMRT is a feasible and safe treatment modality that yields acceptable locoregional control in patients with locally advanced MPM; however, these results should be corroborated in larger studies.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Malignant pleural mesothelioma is an aggressive, deadly cancer often requiring input from multiple medical disciplines. Treatment has evolved over the last several decades with increasing evidence and ongoing advances in chemotherapy, radiation, and immunotherapy; however, no standard treatment regimen has yet been defined. Regardless of the overall strategy, surgery remains the foundation of treatment to remove macroscopic disease, and preservation of lung parenchyma via extended pleurectomy/decortication may be preferable to extrapleural pneumonectomy. PMID: 33012435 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma is an aggressive, deadly cancer often requiring input from multiple medical disciplines. Treatment has evolved over the last several decades with increasing evidence and ongoing advances in chemotherapy, radiation, and immunotherapy; however, no standard treatment regimen has yet been defined. Regardless of the overall strategy, surgery remains the foundation of treatment to remove macroscopic disease, and preservation of lung parenchyma via extended pleurectomy/decortication may be preferable to extrapleural pneumonectomy.
Source: Thoracic Surgery Clinics - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is a rare and extremely aggressive tumor responsible for over 27,000 deaths per year worldwide ([1,2]). First-line therapeutic approaches include surgery, radiations, and chemotherapy ([2,3]). Regrettably, MPMs are refractory to standard treatments, as demonstrated by the short median overall survival rate (9.5 months) ([3]). A new possible treatment opportunity for MPM patients stems from the introduction of a new class of immunotherapeutic drugs, known as immune checkpoint inhibitors (ICI), that has changed the prognosis of several solid tumors ([2,4]).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractBackgroundThe aim of our study was to present the technique for, and early results of complete laparoscopic pelvic peritonectomy (LPP) plus hyperthermic intraperitoneal chemotherapy (HIPEC).MethodsWe conducted a study on consecutive patients who had LPP for limited peritoneal carcinomatosis (peritoneal carcinomatosis index  
Source: Techniques in Coloproctology - Category: Surgery Source Type: research
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group. Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll. Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We thank M. Soucisse et  al. for their informed reply and perspective related to the treatment of rare peritoneal surface malignancies, such as pseudomyxoma peritonei and mesothelioma. While we appreciate that level one evidence may be difficult or impossible to generate for rare cancers, the Program in Evidence Based Car e has defined a rigorously developed process to systematically search for, identify and analyse primary study evidence. The process is not meant to provide a complete summary of all the available evidence but to identify studies that are relevant for the formulation of recommendations.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | History of Medicine | Mesothelioma | Study | Toxicology